Author

A. Shirakabe

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Stepwise intensification of guideline-directed medical therapy is associated with reduced major adverse kidney events in patients with HFpEF and diabetes

Diabetes mellitus is the leading cause of chronic kidney disease and is strongly associated with cardiovascular and all-cause mortality. Heart failure with preserved ejection fraction (HFpEF) frequently coexists with diabetes and confers high cardiorenal risk. Contemporary management of diabetic kidney disease is...

Y. Hoshika, Y. Kubota, T. Nishino et al. · European Heart Journal · 0 citations

Aug 2026

Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI.

BACKGROUND The safety of omitting up-front treatment with aspirin during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) remains unclear. METHODS We conducted a multicenter, open-label, randomized trial in Japan involving patients with STEMI who wer...

Kuniaki Takahashi, Ken Kozuma, Yoshihiro Morino et al. · New England Journal of Medic... · 0 citations

Open access Aug 2026

Sirt1 inhibits the recruitment of RNA polymerase II to metabolic gene promoter during pressure overload through competition with the preinitiation complex on Sub1.

Sirt1 impairs metabolic gene transcription during PO by competitively inhibiting Sub1-mediated recruitment of GTFs and PIC formation, which contributes to the metabolic disturbance and may represent a maladaptive component of the heart failure phenotype.

Shin-ichi Oka, Youssef Mourad, Samta Veera et al. · Cardiovascular Research · 0 citations